Skip to main content

Advertisement

SpringerLink
Log in

Curative Approach for Stage IV Colorectal Cancer with Multiorgan Involvement: What Makes Sense and What Doesn’t?

  • Published:
Current Colorectal Cancer Reports

An Erratum to this article was published on 01 May 2010

Abstract

In 2009, there were almost 150,000 cases of colorectal cancer in the United States. Surgical resection of isolated metastatic pulmonary and hepatic disease has demonstrated a 10-year overall survival rate approaching 30%. The data on definitive management in multiorgan disease are not clear and are limited because of small patient cohorts, the nonrandomized nature of studies, and suboptimal chemotherapeutic agents. Current trials demonstrate that long-term survival is feasible in carefully selected patients with multiorgan metastases, including hepatic and extrahepatic involvement. Following is a review of current literature supporting the potentially curative approach to synchronous and metachronous multiorgan metastatic colorectal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225–249.

    Article  PubMed  Google Scholar 

  2. Yoo PS, Lopez-Soler RI, Longo WE, et al.: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 2006, 6:202–207.

    Article  CAS  PubMed  Google Scholar 

  3. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309–318; discussion 318–321.

    Article  CAS  PubMed  Google Scholar 

  4. Scheele J, Stang R, Altendorf-Hofmann A, et al.: Resection of colorectal liver metastases. World J Surg 1995, 19:59–71.

    Article  CAS  PubMed  Google Scholar 

  5. Jamison RL, Donohue JH, Nagorney DM, et al.: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997, 132:505–510; discussion 511.

    CAS  PubMed  Google Scholar 

  6. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235:759–766.

    Article  PubMed  Google Scholar 

  7. Rees M, Tekkis PP, Welsh FK, et al.: Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008, 247:125–135.

    Article  PubMed  Google Scholar 

  8. Cummings LC, Payes JD, Cooper GS: Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 2007, 109:718–726.

    Article  PubMed  Google Scholar 

  9. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25:4575–4580.

    Article  PubMed  Google Scholar 

  10. Pfannschmidt J, Dienemann H, Hoffmann H: Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007, 84:324–338.

    Article  PubMed  Google Scholar 

  11. McCormack PM, Burt ME, Bains MS, et al.: Lung resection for colorectal metastases. 10-year results. Arch Surg 1992, 127:1403–1406.

    CAS  PubMed  Google Scholar 

  12. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.

    PubMed  Google Scholar 

  13. Saltz LB, Clarke S, Diaz-Rubio E, et al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013–2019.

    Article  CAS  PubMed  Google Scholar 

  14. •• Folprecht G, Gruenberger T, Bechstein WO, et al.: Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38–47. This study demonstrated that with neoadjuvant therapy, patients with previously unresectable disease may become candidates for resection, with an increase in resectability from 32% to 60%.

  15. Adam R, Aloia T, Levi F, et al.: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25:4593–4602.

    Article  CAS  PubMed  Google Scholar 

  16. Scheithauer W, Rosen H, Kornek GV, et al.: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306:752–755.

    Article  CAS  PubMed  Google Scholar 

  17. Adam R, Wicherts DA, de Haas RJ, et al.: Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009, 27:1829–1835.

    Article  PubMed  Google Scholar 

  18. Adam R, Avisar E, Ariche A, et al.: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001, 8:347–353.

    Article  CAS  PubMed  Google Scholar 

  19. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007–1016.

    Article  CAS  PubMed  Google Scholar 

  20. Regnard JF, Grunenwald D, Spaggiari L, et al.: Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998, 66:214–218; discussion 218–219.

    Article  CAS  PubMed  Google Scholar 

  21. Murata S, Moriya Y, Akasu T, et al.: Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998, 83:1086–1093.

    Article  CAS  PubMed  Google Scholar 

  22. Nagakura S, Shirai Y, Yamato Y, et al.: Simultaneous detection of colorectal carcinoma liver and lung metastases does not warrant resection. J Am Coll Surg 2001, 193:153–160.

    Article  CAS  PubMed  Google Scholar 

  23. Kobayashi K, Kawamura M, Ishihara T: Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 1999, 118:1090–1096.

    Article  CAS  PubMed  Google Scholar 

  24. Lehnert T, Knaebel HP, Duck M, et al.: Sequential hepatic and pulmonary resections for metastatic colorectal cancer. Br J Surg 1999, 86:241–243.

    Article  CAS  PubMed  Google Scholar 

  25. Neeff H, Horth W, Makowiec F, et al.: Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg 2009, 13:1813–1820.

    Article  PubMed  Google Scholar 

  26. Miller G, Biernacki P, Kemeny NE, et al.: Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007, 205:231–238.

    Article  PubMed  Google Scholar 

  27. Mineo TC, Ambrogi V, Tonini G, et al.: Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg 2003, 197:386–391.

    Article  PubMed  Google Scholar 

  28. Headrick JR, Miller DL, Nagorney DM, et al.: Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001, 71:975–979; discussion 979–980.

    Article  CAS  PubMed  Google Scholar 

  29. Shah SA, Haddad R, Al-Sukhni W, et al.: Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg 2006, 202:468–475.

    Article  PubMed  Google Scholar 

  30. Robinson BJ, Rice TW, Strong SA, et al.: Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 1999, 117:66–75; discussion 75–76.

    Article  CAS  PubMed  Google Scholar 

  31. Al-Shammaa HA, Li Y, Yonemura Y: Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008, 14:1159–1166.

    Article  PubMed  CAS  Google Scholar 

  32. Jayne DG, Fook S, Loi C, et al.: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002, 89:1545–1550.

    Article  CAS  PubMed  Google Scholar 

  33. Chu DZ, Lang NP, Thompson C, et al.: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989, 63:364–367.

    Article  CAS  PubMed  Google Scholar 

  34. Koppe MJ, Boerman OC, Oyen WJ, et al.: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006, 243:212–222.

    Article  PubMed  Google Scholar 

  35. Sadeghi B, Arvieux C, Glehen O, et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88:358–363.

    Article  CAS  PubMed  Google Scholar 

  36. •• Verwaal VJ, Bruin S, Boot H, et al.: 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008, 15:2426–2432. This is the only phase 3 randomized study to demonstrate a benefit from CRS and HIPEC over palliative chemotherapy in patients with CRPC, with an improvement in OS. This benefit remained after an 8-year follow-up (original study reported by Verwaal et al. [40]).

  37. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995, 221:124–132.

    Article  CAS  PubMed  Google Scholar 

  38. Witkamp AJ, de Bree E, Kaag MM, et al.: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001, 37:979–984.

    Article  CAS  PubMed  Google Scholar 

  39. Elias D, Benizri E, Di Pietrantonio D, et al.: Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. Ann Surg Oncol 2007, 14:509–514.

    Article  PubMed  Google Scholar 

  40. Verwaal VJ, van Ruth S, de Bree E, et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737–3743.

    Article  PubMed  Google Scholar 

  41. Glehen O, Kwiatkowski F, Sugarbaker PH, et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004, 22:3284–3292.

    Article  CAS  PubMed  Google Scholar 

  42. Gomez Portilla A, Barrios P, Rufian S, et al.: Management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 2006, 32:628–631.

    Article  CAS  PubMed  Google Scholar 

  43. Mahteme H, Hansson J, Berglund A, et al.: Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004, 90:403–407.

    Article  CAS  PubMed  Google Scholar 

  44. Elias D, Lefevre JH, Chevalier J, et al.: Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009, 27:681–685.

    Article  PubMed  Google Scholar 

  45. Sugarbaker PH, Schellinx ME, Chang D, et al.: Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 1996, 20:585–591; discussion 592.

    Article  CAS  PubMed  Google Scholar 

  46. Carmignani CP, Ortega-Perez G, Sugarbaker PH: The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol 2004, 30:391–398.

    Article  CAS  PubMed  Google Scholar 

  47. Elias D, Pocard M, Sideris L, et al.: Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 2004, 91:455–456.

    Article  CAS  PubMed  Google Scholar 

  48. Shen P, Hawksworth J, Lovato J, et al.: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 2004, 11:178–186.

    Article  PubMed  Google Scholar 

  49. Shen P, Thai K, Stewart JH, et al.: Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol 2008, 15:3422–3432.

    Article  PubMed  Google Scholar 

  50. Yan TD, Chu F, Links M, et al.: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. Eur J Surg Oncol 2006, 32:1119–1124.

    Article  CAS  PubMed  Google Scholar 

  51. Kianmanesh R, Scaringi S, Sabate JM, et al.: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 2007, 245:597–603.

    Article  PubMed  Google Scholar 

  52. Varban O, Levine EA, Stewart JH, et al.: Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. Cancer 2009, 115:3427–3436.

    Article  PubMed  Google Scholar 

  53. Chua TC, Yan TD, Zhao J, et al.: Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol 2009, 35:1299–1305.

    CAS  PubMed  Google Scholar 

  54. Elias D, Benizri E, Pocard M, et al.: Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol 2006, 32:632–636.

    Article  CAS  PubMed  Google Scholar 

  55. Esquivel J, Sticca R, Sugarbaker P, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007, 14:128–133.

    CAS  PubMed  Google Scholar 

  56. Blumgart LH, Fong Y: Surgical options in the treatment of hepatic metastasis from colorectal cancer. Curr Probl Surg 1995, 32:333–421.

    Article  CAS  PubMed  Google Scholar 

  57. Elias D, Saric J, Jaeck D, et al.: Prospective study of microscopic lymph node involvement of the hepatic pedicle during curative hepatectomy for colorectal metastases. Br J Surg 1996, 83:942–945.

    Article  CAS  PubMed  Google Scholar 

  58. Laurent C, Sa Cunha A, Rullier E, et al.: Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg 2004, 198:884–891.

    Article  PubMed  Google Scholar 

  59. Rosen CB, Nagorney DM, Taswell HF, et al.: Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg 1992, 216:493–504; discussion 504–505.

    Article  CAS  PubMed  Google Scholar 

  60. Jaeck D, Nakano H, Bachellier P, et al.: Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 2002, 9:430–438.

    Article  PubMed  Google Scholar 

  61. Adam R, de Haas RJ, Wicherts DA, et al.: Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J Clin Oncol 2008, 26:3672–3680.

    Article  PubMed  Google Scholar 

  62. Oussoultzoglou E, Romain B, Panaro F, et al.: Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Surg 2009, 249:879–886.

    Article  PubMed  Google Scholar 

  63. Grobmyer SR, Wang L, Gonen M, et al.: Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006, 244:260–264.

    Article  PubMed  Google Scholar 

  64. Elias D, Ouellet JF, Bellon N, et al.: Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003, 90:567–574.

    Article  CAS  PubMed  Google Scholar 

  65. Elias D, Sideris L, Pocard M, et al.: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004, 11:274–280.

    Article  PubMed  Google Scholar 

  66. Carpizo DR, D’Angelica M: Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Ann Surg Oncol 2009, 16:2411–2421.

    Article  PubMed  Google Scholar 

  67. •• Elias D, Liberale G, Vernerey D, et al.: Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol 2005, 12:900–909. This study introduced a novel idea: it is not the site but the number of metastases that makes a difference in the OS of patients.

  68. National Comprehensive Cancer Network guidelines. Available at http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Northwestern University Feinberg School of Medicine, 676 North St. Clair, Suite 850, Chicago, IL, 60611, USA

    Polina Khrizman & Mary F. Mulcahy

Authors
  1. Polina Khrizman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mary F. Mulcahy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary F. Mulcahy.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s11888-010-0058-x

Rights and permissions

Reprints and permissions

About this article

Cite this article

Khrizman, P., Mulcahy, M.F. Curative Approach for Stage IV Colorectal Cancer with Multiorgan Involvement: What Makes Sense and What Doesn’t?. Curr Colorectal Cancer Rep 6, 97–107 (2010). https://doi.org/10.1007/s11888-010-0050-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-010-0050-5

Keywords

Search

Navigation